Introduction {#s1}
============

A shared characteristic of cancers of the oesophagus and the stomach is the poor overall prognosis. The reported overall 5-year survival rate in oesophageal cancer in Europe is about 10%, and the corresponding rate for gastric cancer is about 20% [@pone.0041352-Sant1]. There is a need to assess potential changes in the prognosis of these tumours. Sweden offers excellent opportunities to assess population-based survival in cancer. There is a complete assessment of all individuals through the personal identity numbers; [@pone.0041352-Ludvigsson1] the Swedish Cancer Register has a complete recording of oesophageal and gastric cancer; [@pone.0041352-Ekstrom1], [@pone.0041352-Lindblad1] data on dates of death and emigration is complete by virtue of the Register of the Total Population. Therefore, survival studies from Sweden can be conducted in a population-based design. We have previously reported the survival rates in oesophageal cancer in Sweden until year 1996, showing that the relative 5-year survival had improved from about 5% to about 10% in both squamous cell carcinoma and adenocarcinoma of the oesophagus during the 1990s [@pone.0041352-Sundelof1]. The present study was conducted to provide recent population-based survival rates in oesophageal and gastric cancers by histological type and by subsite.

Materials and Methods {#s2}
=====================

Ethics statement {#s2a}
----------------

The study was approved by the Regional Ethical Review Board in Stockholm.

Study design {#s2b}
------------

This was a nationwide Swedish population-based cohort study of the standardised relative survival rates in oesophageal squamous cell carcinoma, oesophageal adenocarcinoma, gastric cardia adenocarcinoma, and gastric non-cardia adenocarcinoma. All residents in Sweden were eligible for the study. The total study period included the years 1961--2008, with follow-up until end of 2009. The focus of the present study was on the period after 1996, i.e. the years after those included in our previous publication addressing oesophageal cancer survival. [@pone.0041352-Sundelof1] The Swedish Cancer Register was used to identify all cases of oesophageal or gastric cancer. The Swedish Register of the Total Population was used to identify dates of mortality, and to exclude person-time no longer at risk of cancer recorded in the Cancer Register due to emigration.

Data collection {#s2c}
---------------

This Swedish Cancer Register was established in 1958 and has an at least 96% complete registration of the type and date of diagnosis of all cancers in Sweden since 1961 [@pone.0041352-Barlow1]. The completeness for both oesophageal and gastric cancer is 98% according to comprehensive validation studies [@pone.0041352-Ekstrom1], [@pone.0041352-Lindblad1]. The 2% non-registration is mainly due to missing of sending in the forms for registration to the Swedish Cancer Registry. The Cancer Register used the 7^th^ version of the International Classification of Diagnoses (ICD-7) for coding of cancer diagnoses. Oesophageal cancer was coded as ICD-7 code 150, while gastric cardia cancer was coded as 151.1, and gastric non-cardia was coded as 151.0, 151.8 or 151.9. The histology code (WHO/HS/CANC/24.1 Histology Code) for adenocarcinoma was 096, while it was 146 for squamous cell carcinoma. [Table 1](#pone-0041352-t001){ref-type="table"} shows how the ICD-7 and WHO/HS/CANC/24.1 coding systems compare to the ICD-10 and the ICD-O topographic and morphological classifications. Only since 2004 tumour stage has been recorded in the Swedish Cancer Registry. The 6^th^ edition of the TNM stage from 2002 was used according to the Union Internationale Contre le Cancer [@pone.0041352-Greene1]. The assessment of the staging was done by the clinician who reported the cancer case to the Cancer Registry. Data on the specific site gastric cardia cancer was available from 1970. The personal identity number was used to link all individual cohort members to the Register of the Total Population, a register with 100% completeness of dates of death and emigration. This register provided accurate dates of all deaths during the follow-up of the study cohort, and also included data on emigration.

10.1371/journal.pone.0041352.t001

###### The 7^th^ and 10^th^ version of the International Classification of Diagnoses (ICD) for coding of oesophageal and gastric cancer diagnoses, and the histology codes for adenocarcinoma and squamous cell carcinoma in the WHO/HS/CANC/24.1 Histology.

![](pone.0041352.t001){#pone-0041352-t001-1}

  Cancer type                                   ICD-7                                  ICD-10                           WHO/HS/CANC/24   ICD-O
  ------------------------------------- --------------------- -------------------------------------------------------- ---------------- -------
  Oesophageal squamous cell carcinoma            150                                    C15                                  146          807
  Oesophageal adenocarcinoma                     150                                    C15                                  096          814
  Gastric cardia adenocarcinoma                 151.1                                  C16.0                                 096          814
  Gastric non-cardia adenocarcinoma      151.0, 151.8, 151.9   C16.1, C16.2, C16.3, C16.4, C16.5, C16.6, C16.8, C16.9        096          814

Code and the ICD-O classification.

![Relative survival rates (%) in defined calendar year periods of diagnosis in oesophageal squamous cell carcinoma and oesophageal adenocarcinoma in 1961--2008, and cardia adenocarcinoma and gastric non-cardia adenocarcinoma in 1970--2008, and follow-up until 2009 in Sweden.](pone.0041352.g001){#pone-0041352-g001}

Statistical analysis {#s2d}
--------------------

Observed and relative survival rates were calculated for survival 1 year, 3 years, and 5 years after diagnosis. Calendar periods were evaluated separately. For the most recent calendar period, 2000--2008, the results were also stratified for sex and age groups, while stratification for tumour stage was possible for the period 2004--2008. Observed survival rates with 95% confidence intervals (CI) were estimated using the life-table method [@pone.0041352-Cutler1]. Relative survival rates with 95% CI were the main outcome measure since it estimates the disease-specific survival. Relative survival rates were computed as the ratio of the observed to the expected survival, where the expected survival represented the survival among the entire Swedish population in the same age, sex, and calendar year. All analyses were performed using SAS Statistical Package (version 9.2, SAS Institute Inc., Gary, NC).

Results {#s3}
=======

Survival in oesophageal squamous cell carcinoma {#s3a}
-----------------------------------------------

Among 9,616 oesophageal squamous cell carcinomas, a majority were men (66.6%). The improvement in survival rates seen during the years 1961--1999 did not continue during the period 2000--2008 ([Table 2](#pone-0041352-t002){ref-type="table"}, [Figure 1](#pone-0041352-g001){ref-type="fig"}). The 5-year relative survival rate was 10.5% (95% CI 9.0%--11.9%) in 1990--1999 and 10.3% (95% CI 8.5%--12.0%) in 2000--2008. The survival rates in 2000--2008 were slightly better in women compared to men, and older age was associated with worse relative survival ([Table 3](#pone-0041352-t003){ref-type="table"}).

10.1371/journal.pone.0041352.t002

###### Observed and relative survival rates (%) in patients with oesophageal squamous cell carcinoma and oesophageal adenocarcinoma in 1961--2008, and cardia adenocarcinoma and gastric non-cardia adenocarcinoma in 1970--2008, and follow-up until 2009 in Sweden.

![](pone.0041352.t002){#pone-0041352-t002-2}

                                                         Observed survival rate (95% confidence interval)   Relative survival rate (95% confidence interval)                                                                
  ------------------------- ------------ ------- ------ -------------------------------------------------- -------------------------------------------------- ------------------- --------------------- ------------------- -------------------
  **Esophageal squamous**    1961--1969   1414    68.9                  24.8 (22.5--27.0)                                    6.6 (5.3--7.9)                     4.3 (3.2--5.3)      26.1 (23.7--28.4)     7.5 (6.0--9.0)      5.0 (3.8--6.3)
  **cell carcinoma**         1970--1979   1942    69.2                  27.3 (25.4--29.3)                                    8.4 (7.1--9.8)                     6.0 (4.8--7.1)     28.8 (26.7----30.8)    9.4 (7.9--10.9)     7.1 (5.7--8.4)
                             1980--1989   2353    69.9                  31.2 (29.3--33.1)                                   10.1 (8.7--11.5)                    7.4 (6.2--8.6)      32.8 (30.8--34.7)    11.2 (9.7--12.7)     8.6 (7.2--10.0)
                             1990--1999   2252    70.0                  33.5 (31.6--35.5)                                   12.5 (11.1--14)                     9.3 (8.0--10.6)     35.0 (33.0--37.1)     13.6 (12--15.2)    10.5 (9.0--11.9)
                             2000--2008   1655    70.1                  35.3 (33.0--37.7)                                  13.4 (11.6--15.1)                    9.3 (7.8--10.9)     36.7 (34.3--39.1)    14.3 (12.4--16.1)   10.3 (8.5--12.0)
  **Esophageal**             1961--1969    215    67.4                  29.8 (23.7--35.9)                                   7.0 (3.6--10.4)                     5.6 (2.5--8.6)      31.1 (24.7--37.5)     7.8 (4.0--11.6)     6.6 (3.0--10.2)
  **adenocarcinoma**         1970--1979    360    69.3                  27.2 (22.6--31.8)                                    6.1 (3.5--8.7)                     3.2 (1.3--5.1)      28.7 (23.9--33.6)     6.8 (3.9--9.8)      3.7 (1.4--5.9)
                             1980--1989    531    70.1                  29.4 (25.5--33.3)                                   7.6 (5.1--10.1)                     5.9 (3.7--8.1)      31.1 (27.0--35.2)      8.3 (5.6--11)      6.7 (4.2--9.2)
                             1990--1999    909    70.3                  35.6 (32.5--38.8)                                  16.4 (13.9--18.8)                   10.6 (8.5--12.6)     37.4 (34.2--40.7)    18.1 (15.4--20.8)   12.5 (10.1--14.9)
                             2000--2008   1707    69.6                  40.1 (37.7--42.4)                                  17.1 (15.2--19.0)                   13.1 (11.3--14.8)    41.8 (39.4--44.2)    18.4 (16.4--20.4)   14.6 (12.6--16.6)
  **Gastric cardia**         1970--1979    951    68.3                  27.3 (24.5--30.2)                                   8.8 (6.9--10.7)                     4.9 (3.4--6.3)      28.7 (25.7--31.7)     9.7 (7.6--11.7)     5.6 (3.9--7.3)
  **adenocarcinoma**         1980--1989   1563    69.9                  36.6 (34.2--39.0)                                  12.6 (10.8--14.3)                    8.8 (7.3--10.3)     38.5 (36.0--41.0)    13.8 (11.9--15.8)   10.3 (8.5--12.0)
                             1990--1999   1981    69.9                  37.1 (34.9--39.2)                                  13.8 (12.2--15.3)                    9.6 (8.3--10.9)     38.9 (36.7--41.2)    15.2 (13.5--16.9)   11.1 (9.6--12.6)
                             2000--2008   1743    69.2                  41.0 (38.7--43.3)                                  17.5 (15.6--19.3)                   12.4 (10.7--14.1)    42.7 (40.3--45.1)    19.1 (17.0--21.1)   14.3 (12.3--16.3)
  **Gastric non--cardia**    1970--1979   15520   70.1                  35.1 (34.4--35.9)                                  16.8 (16.2--17.5)                   12.5 (11.9--13.1)    37.2 (36.4--38.0)    19.0 (18.2--19.7)   15.2 (14.5--15.9)
  **adenocarcinoma**         1980--1989   14260   72.1                  43.7 (42.9--44.5)                                  22.3 (21.5--23.1)                   16.9 (16.2--17.6)    46.5 (45.6--47.3)    25.3 (24.5--26.2)   20.7 (19.9--21.6)
                             1990--1999   9619    72.8                  42.0 (41.0--43.0)                                  21.9 (21.0--22.7)                   16.5 (15.7--17.3)    44.5 (43.5--45.6)    24.9 (23.9--25.8)   20.2 (19.2--21.1)
                             2000--2008   5876    73.1                  41.4 (40.2--42.7)                                  20.4 (19.3--21.5)                   15.7 (14.7--16.8)    43.8 (42.5--45.1)    23.0 (21.8--24.2)   19.0 (17.7--20.2)

10.1371/journal.pone.0041352.t003

###### Relative survival rates (%) in patients with oesophageal squamous cell carcinoma, oesophageal adenocarcinoma, gastric cardia adenocarcinoma and gastric non-cardia adenocarcinoma in Sweden in 2000--2008, and follow-up until 2009.

![](pone.0041352.t003){#pone-0041352-t003-3}

                                                                  Relative survival rate (95% confidence interval)                      
  ------------------------- ------------- -------- ------------- -------------------------------------------------- ------------------- -------------------
  **Esophageal squamous**        Sex        Men     1025 (61.9)                  35.6 (32.6--38.6)                   13.1 (10.9--15.4)    9.6 (7.5--11.7)
  **cell carcinoma**                       Women    630 (38.1)                   38.6 (34.7--42.5)                   16.1 (12.9--19.2)   11.4 (8.4--14.4)
                             Age (years)    \<60    301 (18.2)                   50.4 (44.7--56.1)                   21.0 (16.2--25.8)   16.0 (11.4--20.6)
                                           60--69   454 (27.4)                   40.8 (36.2--45.3)                   15.8 (12.2--19.4)   13.0 (9.4--16.6)
                                           70--79   555 (33.5)                  34.1 (30.0----38.1)                  12.9 (9.8--16.0)     8.9 (6.0--11.7)
                                            ≥80     345 (20.8)                  22.1 (17.4----26.9)                   9.7 (5.7--13.8)     3.7 (0.1--7.6)
  **Esophageal**                 Sex        Men     1386 (81.2)                  42.6 (39.9--45.3)                   19.1 (16.9--21.4)   15.3 (13.0--17.5)
  **adenocarcinoma**                       Women    321 (18.8)                   38.1 (32.6--43.6)                   15.4 (11.1--19.8)   11.7 (7.5--15.9)
                             Age (years)    \<60    344 (20.2)                   48.5 (43.2--53.8)                   21.7 (17.1--26.2)   18.9 (14.4--23.5)
                                           60--69   485 (28.4)                   48.4 (43.9--52.9)                   24.5 (20.4--28.5)   20.8 (16.8--24.9)
                                           70--79   494 (28.9)                   40.5 (36.0--44.9)                   18.4 (14.6--22.1)   13.6 (9.8--17.3)
                                            ≥80     384 (22.5)                   27.5 (22.7--32.4)                    7.8 (4.1--11.6)     3.8 (0.3--7.2)
  **Gastric cardia**             Sex        Men     1331 (76.4)                  44.2 (41.4--47.0)                   19.5 (17.2--21.8)   14.7 (12.4--17.0)
  **adenocarcinoma**                       Women    412 (23.6)                   37.9 (33.0--42.7)                   17.7 (13.6--21.7)   13.1 (9.2--17.1)
                             Age (years)    \<60    384 (22.0)                   51.5 (46.5--56.5)                   22.4 (18.0--26.7)   17.1 (12.8--21.3)
                                           60--69   453 (26.0)                   48.3 (43.6--52.9)                   23.3 (19.2--27.5)   17.4 (13.4--21.5)
                                           70--79   512 (29.4)                   40.4 (36.1--44.8)                   19.0 (15.3--22.8)   14.2 (10.4--18.1)
                                            ≥80     394 (22.6)                   29.1 (24.2--34.0)                   11.6 (7.5--15.7)    10.8 (5.5--16.1)
  **Gastric non--cardia**        Sex        Men     3329 (56.7)                  44.6 (42.8--46.4)                   23.2 (21.6--24.9)   19.1 (17.5--20.7)
  **adenocarcinoma**                       Women    2547 (43.3)                  42.7 (40.7--44.7)                   22.6 (20.8--24.4)   18.8 (16.9--20.6)
                             Age (years)    \<60    826 (14.1)                   52.1 (48.7--55.5)                   28.6 (25.5--31.8)   23.8 (20.6--26.9)
                                           60--69   1137 (19.3)                  48.9 (45.9--51.8)                   25.6 (22.9--28.3)   19.9 (17.2--22.6)
                                           70--79   1897 (32.3)                  44.0 (41.7--46.3)                   24.7 (22.6--26.9)   21.5 (19.3--23.7)
                                            ≥80     2016 (34.3)                  36.5 (34.2--38.8)                   18.1 (15.8--20.3)   15.7 (13.2--18.2)

Survival in oesophageal adenocarcinoma {#s3b}
--------------------------------------

Among 3,722 patients with oesophageal adenocarcinoma, the majority (80.2%) were males. The survival rates improved during the entire study period, including the last decade ([Table 2](#pone-0041352-t002){ref-type="table"}, [Figure 1](#pone-0041352-g001){ref-type="fig"}) (p for trend \<0.001). The relative 5-year survival was 14.6% (95% CI 12.6%--16.6%) in 2000--2008, while it was 12.5% (95% CI 10.1%--14.9%) in 1990--1999. The recent survival rates (2000--2008) were higher in men compared to women, and older age groups had worse survival ([Table 3](#pone-0041352-t003){ref-type="table"}).

Gastric cardia adenocarcinoma {#s3c}
-----------------------------

The cohort included 6,238 patients with gastric cardia adenocarcinoma, of whom 76.4% were men. The survival patterns were similar to those of oesophageal adenocarcinoma, with improved rates during the entire study period, including the most recent period ([Table 2](#pone-0041352-t002){ref-type="table"}, [Figure 1](#pone-0041352-g001){ref-type="fig"}). The 5-year relative survival was 11.1% (95% CI 9.6%--12.6%) in 1990--1999 and 14.3% (95% CI 12.3%--16.3%) in 2000--2008. The recent survival rates were higher among men and younger patients ([Table 3](#pone-0041352-t003){ref-type="table"}).

Gastric non-cardia adenocarcinoma {#s3d}
---------------------------------

Gastric non-cardia adenocarcinoma was found in 45,275 patients, of whom 59.5% were men. After 1980, the survival rates slightly declined ([Table 2](#pone-0041352-t002){ref-type="table"}, [Figure 1](#pone-0041352-g001){ref-type="fig"}). The relative 5-year survival was 19.0% (95% CI 17.7%--20.2%) in 2000--2008, while it was 20.2% (95% CI 19.2%--21.1%) in 1990--1999. The recent survival rates were similar in men and women, and age did not strongly influence the relative survival ([Table 3](#pone-0041352-t003){ref-type="table"}).

Tumour stage-specific survival {#s3e}
------------------------------

Data on tumour stage during the period 2004--2008 revealed that tumour stage was strongly correlated with the relative survival in each of the four types of cancer studied ([Table 4](#pone-0041352-t004){ref-type="table"}). The frequencies of missing data on tumour stage were 28.8%, 28.3%, 24.8%, and 27.3% for oesophageal squamous cell carcinoma, oesophageal adenocarcinoma, gastric cardia adenocarcinoma, and gastric non-cardia adenocarcinoma, respectively. The most advanced tumour stage (IV) represented the largest group of patients in each of the tumour groups, while a low frequency of patients (range 5.8--8.2%) were identified in the earliest tumour stage (I). The 3-year relative survival rates in tumours of stage I ranged from 68.9% for gastric non-cardia adenocarcinoma to 46.7% for oesophageal squamous cell carcinoma. The survival in patients with stage III tumours was similar, about 25%, in all tumour types ([Table 4](#pone-0041352-t004){ref-type="table"}).

10.1371/journal.pone.0041352.t004

###### Tumour-stage specific relative survival rates (%) in patients with oesophageal squamous cell carcinoma, oesophageal adenocarcinoma, gastric cardia adenocarcinoma and gastric non-cardia adenocarcinoma in Sweden in 2004--2008, and follow-up until 2009.

![](pone.0041352.t004){#pone-0041352-t004-4}

                                                            Relative survival rate (95% confidence interval)  
  -------------------------- --------- ------------ ------ -------------------------------------------------- -------------------
  **Oesophageal squamous**     Total       867       70.0                  36.8 (33.5--40.1)                   16.2 (13.5--19.0)
  **cell carcinoma**             I       36 (4.2)    69.1                  68.6 (52.8--84.5)                   46.7 (27.9--65.5)
                                II      188 (21.7)   69.0                  48.3 (41.0--55.7)                   21.6 (15.0--28.3)
                                III     178 (20.5)   69.5                  43.4 (36.0--50.9)                   23.5 (16.8--30.2)
                                IV      215 (24.8)   68.6                  25.3 (19.4--31.3)                    5.9 (2.3--9.6)
                              Missing   250 (28.8)   72.3                  28.6 (22.8--34.4)                   10.8 (6.4--15.3)
  **Oesophageal**              Total       1030      69.5                  41.3 (38.2--44.4)                   19.2 (16.5--21.8)
  **adenocarcinoma**             I       52 (5.0)    67.7                  79.5 (67.7--91.3)                   65.7 (51.6--79.8)
                                II      176 (17.1)   69.8                  59.2 (51.5--66.8)                   31.4 (23.3--39.4)
                                III     239 (23.2)   69.1                  52.4 (45.9--59.0)                   26.1 (20.0--32.2)
                                IV      272 (26.4)   67.3                  21.3 (16.3--26.2)                    3.6 (0.9--6.3)
                              Missing   291 (28.3)   72.1                  33.2 (27.5--38.8)                   11.6 (7.4--15.7)
  **Gastric cardia**           Total       960       68.9                  45.7 (42.4--48.9)                   21.9 (19.0--24.8)
  **adenocarcinoma**             I       43 (4.5)    69.0                  70.0 (55.4--84.5)                   59.8 (43.5--76.2)
                                II      192 (20.0)   69.0                  70.8 (64.0--77.7)                   46.3 (38.4--54.2)
                                III     226 (23.5)   67.6                  63.6 (57.0--70.1)                   25.5 (19.1--31.9)
                                IV      261 (27.2)   66.9                  19.7 (14.8--24.6)                    4.0 (0.9--7.1)
                              Missing   238 (24.8)   72.1                  32.5 (26.3--38.6)                   10.2 (5.9--14.5)
  **Gastric non-cardia**       Total       3001      73.2                  44.1 (42.2--45.9)                   24.3 (22.6--26.1)
  **adenocarcinoma**             I      179 (6.0)    73.0                  79.7 (73.2--86.3)                   68.9 (60.7--77.1)
                                II      509 (17.0)   73.0                  69.9 (65.5--74.2)                   51.2 (46.2--56.3)
                                III     614 (20.5)   72.5                  52.4 (48.2--56.6)                   25.2 (21.3--29.0)
                                IV      879 (29.3)   70.8                  22.4 (19.6--25.2)                    4.7 (3.1--6.4)
                              Missing   820 (27.3)   76.3                  37.3 (33.8--40.8)                   17.4 (14.3--20.4)

Discussion {#s4}
==========

This study indicates that the overall survival rates in oesophageal and gastric cardia adenocarcinoma have improved during the last decade, while such survival rates in oesophageal squamous cell carcinoma and gastric non-cardia adenocarcinoma have been unchanged and declined, respectively. The current (2000--2008) relative 5-year survival rates are about 10%, 15%, 15%, and 20% for oesophageal squamous cell carcinoma, oesophageal adenocarcinoma, gastric cardia adenocarcinoma, and gastric non-cardia adenocarcinoma, respectively.

Methodological strengths include the population-based design, the completeness of the assessment of tumours and mortality, as well as the calculation of relative survival which represents disease-specific mortality. Among limitations, clinical variables were not available, including treatment, co-morbidity, and other prognostic factors. The purpose of the study was, however, to evaluate only the overall survival, independent of clinical factors. Nevertheless, we did analyse the tumour stage-specific survival, which was available from 2004, although a proportion of data was missing.

The diverging patterns of survival between the studied tumours are intriguing. We can only speculate about possible reasons for these changes, particularly since we lack data on the treatment. The dramatic changes in incidence of oesophageal and gastric cancer during recent decades might for example contribute to these findings. The incidence of oesophageal and gastric cardia adenocarcinoma has increased markedly, while the incidence of gastric non-cardia adenocarcinoma and oesophageal squamous cell carcinoma has decreased over many years.[@pone.0041352-Lagergren1]--[@pone.0041352-Brown1] An increased awareness of tumours near the gastro-oesophageal junction among clinicians might have contributed to earlier detection. Moreover, the increased incidence might have increased the clinical experience in the treatment of these tumours, including surgical procedures and postoperative care. An increased centralisation of the surgical treatment of oesophageal cancer to fewer and larger centres has occurred in many countries during the recent few years, including Sweden, and this might have contributed to the better survival rates in oesophageal adenocarcinoma, but the lack of such improvement in oesophageal squamous cell carcinoma argue against this possibility.[@pone.0041352-Stitzenberg1], [@pone.0041352-Wouters1] Another potentially relevant factor regarding long-term results in the treatment of oesophageal and gastric cancer is an increased implementation of multi-disciplinary approach and multidisciplinary team meetings, which might result in more accurate clinical decision-making and a better tailoring of the treatment for the individual patient.[@pone.0041352-Davies1] However, the differences in survival patterns between the tumours reported in this study do not entirely fit with the influence of multi-disciplinary approach.

In agreement with the present study, a recent population-based study from 1988-2005 in the US found similar survival rates and changes in survival over time in oesophageal and cardia adenocarcinoma, which indicate that these tumours might not be distinct disease entities.[@pone.0041352-Whitson1] A small population-based study from Minnesota in the United States showed no strong changes in survival with time in oesophageal or gastric adenocarcinoma during the period 1971--2000.[@pone.0041352-Crane1] Our previous population-based study of oesophageal cancer survival showed an improved relative survival during the 1990s compared to previous decades for both adenocarcinoma and squamous cell carcinoma.[@pone.0041352-Sundelof2]

The reasons behind the changing trends in survival in these tumours should be addressed in future research. The influence of the treatment, co-morbidities and other known prognostic factors should be included in studies addressing explanations for the time trends in the overall survival.

In conclusion, this population-based study reveals an encouraging improvement in the overall relative survival rates in oesophageal and cardia adenocarcinoma, while no such improvement was found for oesophageal squamous cell carcinoma or gastric non-cardia adenocarcinoma.
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